Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Rapid Readout: T-DXd in Patients With HER2+ Unresectable or Metastatic Gastric or GEJ Following a Trastuzumab-Containing Regimen

October 27th 2021

Ronan Kelly, MD, MBA, discusses data from the presentation “Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen.” (Van Cutsem et al, ESMO 2021, LBA55)

Future Landscape of HER2+ MBC

October 26th 2021

Drs. Sara Tolaney and Mark Pegram discuss promising therapies and upcoming mechanisms of actions to treat HER2+ metastatic breast cancer.

Other Trials with Trastuzumab Deruxtecan in Breast Cancer

October 26th 2021

Breast cancer experts, Drs. Sara Tolaney and Mark Pegram discuss ongoing and noteworthy trials with trastuzumab deruxtecan in mBC.

Sequencing in HER2+ MBC

October 26th 2021

Sara Tolaney, MD, and Mark Pegram, MD, discuss their rationale for sequencing of most effective therapy in treatment of patients with metastatic breast cancer.

Updates in HER2+ Breast Cancer from ESMO 2021

October 25th 2021

Expert oncologists discuss data from several phase 2 and phase 3 trials presented at ESMO 2021 on the use of trastuzumab deruxtecan for HER2-positive breast cancer and how it impacts their practices.

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC

October 22nd 2021

The European Commission has approved pembrolizumab plus chemotherapy for the frontline treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors have a PD-L1 expression combined positive score of 10 or higher and who have not previously received chemotherapy for metastatic disease.

Multidisciplinary Care in ILD Management: Role of a Pulmonologist

October 22nd 2021

Shared insight on the benefit of multidisciplinary care and the pulmonologist’s role in identifying and managing interstitial lung disease.

Understanding the Risk-Benefit Comparison of Agents That May Cause ILD

October 22nd 2021

Key opinion leaders share risk-benefit considerations when utilizing therapies that may increase a patient’s risk of developing ILD.

Experience with Trastuzumab Deruxtecan in Breast Cancer

October 21st 2021

Breast cancer experts, Sara Tolaney, MD, and Mark Pegram, MD, discuss current standard of care in sequencing of therapies in mBC and the effect of DESTINY-Breast03 data on sequencing going forward.

DESTINY-Breast03 Trial in HER2+ mBC

October 21st 2021

Mark Pegram, MD, and Sara Tolaney, MD, review the DESTINY-Breast03 study design, clinical efficacy, and safety data.

Trastuzumab Derxutecan in HER2+ mBC

October 21st 2021

Sara Tolaney, MD, describes trastuzumab deruxtecan and the data that led to its accelerated approval in HER2+ breast cancer.

Historical Perspective of HER2+ Breast Cancer

October 21st 2021

Mark Pegram, MD, provides a historical perspective on recent advancements made in the treatment landscape for patients with HER2-positive breast cancer.

Elacestrant Improves PFS Over SOC in ER+ Advanced or Metastatic Breast Cancer

October 20th 2021

Elacestrant monotherapy improved progression-free survival over standard-of-care (SOC) treatment in patients with estrogen receptor–positive, HER2-negative breast cancer, including those whose tumors harbored ESR1 mutations, meeting the primary end points of the phase 3 EMERALD trial.

Study Highlights Racial, Ethnic Disparities in Post-Breast Cancer Surgery Emergency Department Visits

October 19th 2021

Non-Hispanic Black women are approximately 40% more like to require a visit to the emergency department after breast cancer surgery, and Hispanic women are 11% more likely compared with non-Hispanic White women, according to results from a population-based study published in Breast Cancer Research and Treatment.

Sacituzumab Govitecan May Be New Standard of Care in Metastatic TNBC

October 19th 2021

Hope S. Rugo, MD, FASCO, provides her insights on the final analysis data from the international phase 3 ASCENT trial.

New Subcutaneous, Oral, and Intravenous Therapies Transform Treatment in Early-Stage HER2+ Breast Cancer

October 18th 2021

Francisco Javier Esteva, MD, PhD, discussed the current approach to treating patients with early-stage HER2-positive breast cancer, unmet needs in the space, and future directions with neratinib and T-DM1.

Role of Bronchoscopy in Identifying and Managing ILD

October 15th 2021

Charles A. Powell, MD, MBA, leads a discussion on bronchoscopy’s role in identifying interstitial lung disease.

Optimizing the Management of ILD: Steroids, Therapy Cessation, and Dose Modification

October 15th 2021

A broad review of strategies to manage interstitial lung disease, including steroid use, therapy cessation/rechallenging, and dose reduction.

FDA Greenlights Companion Diagnostic for Adjuvant Abemaciclib Plus Endocrine Therapy in High-Risk Early Breast Cancer

October 14th 2021

The FDA has approved the Ki-67 IHC MIB-1 pharmDx test to assist in determining which patients with early breast cancer who are at high risk of disease recurrence might benefit from adjuvant treatment with abemaciclib plus endocrine therapy.

FDA Approves Adjuvant Abemaciclib Plus Endocrine Therapy for Select HR+ Early Breast Cancer

October 13th 2021

The FDA has approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of 20% or higher, as determined by an FDA-approved test.